((自动化翻译由路透提供，请见免责声明 ))
9月27日 - ** 制药商百时美施贵宝 股价盘前上涨6.40%至53.33美元
** 美国食品和药物管理局批准了 (link) 公司的精神分裂症药物，为患者提供了一种可减轻精神障碍症状且无常见副作用的治疗选择。
** BMY 以 140 亿美元的价格收购了 Karuna Therapeutics 公司，从而获得了 Cobenfy（又称 KarXT）这种药物。
** 该药预计将于 10 月下旬向患者提供，上市价格为每月 1,850 美元或每年约 22,500 美元。
** BMO Capital Markets表示，该药在无黑框警告的情况下获得批准，对布里斯托尔公司和患者来说都是一个重大利好消息
** 券商预计该药的销售峰值为 24 亿美元
** 截至收盘，该股今年累计下跌 2.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.